On December 8th, 3billion was selected as a finalist of the Novartis Korea’s Health X-Challenge Seoul for the ‘Genetic retinal disease’ category. 3billion was highly praised for introducing AI to rare disease diagnosis and thus doubling the accuracy of variant interpretation and lowering the time and cost of diagnosis.

3billion plans to streamline the process from diagnosis to treatment for patients with hereditary retinal diseases.

Original article: Medifonews. 노바티스, 제2회 '헬스엑스 챌린지 서울' 최종 선정기업 발표